Role of Intralesional Bleomycin in the Treatment of Complicated Hemangiomas: Prospective Clinical Study

Omidvari, Shapour; Nezakatgoo, Nosratollah; Ahmadloo, Niloofar; Mohammadianpanah, Μohammad; Ahmad, Mansoor

doi:10.1111/j.1524-4725.2005.31150

Cited by 22 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Proper injections into the vascular spaces leads to gradual fibrous degeneration and resultant lesion regression, with no fibrosis and scarring. It is a minimally invasive treatment with good results, and has therefore been in use for last two decades (2,3,9,13,28,33).…”

Section: Discussionmentioning

confidence: 99%

“…It has sclerosing properties on direct contact with endothelium. Compared to surgery, intralesional bleomycin injection (IBI) is a simple, practical and noninvasive method of treatment that limits the number of secondary procedures (2,3). BLM was first isolated as a Cu2+-containing glyco-oligopeptide antibiotic from the culture medium of streptomyces verticullust.…”

Section: Introductionmentioning

confidence: 99%

“…Studies show that sclerotherapy is good for small diameter vessels. Therefore, intralesional injection of bleomycin in the cervical-facial region has been a routine therapy and has proven to be effective for the last 20 years (2,3,8,9).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Memon

Malik

Anjum

et al. 2016

JGR

View full text Add to dashboard Cite

Purpose: To report the therapeutic outcome of ultrasound-guided intralesional injection of bleomycin in the treatment of cutaneous hemangiomas and vascular malformations. Material & Methods:The medical records of patients with cutaneous hemangiomas and vascular malformations treated with the intralesional injection of bleomycin under ultrasound guidance between August 2009 and June 2013 at the Indus Hospital, Karachi were reviewed retrospectively using a computerized medical record information management system. Data were extracted using a pre-coded performa that included patient demographics, type and location of lesion, number of treatments, presenting/pre-and post-treatment clinical symptoms (pain, swelling, heaviness, size, discoloration), ultrasound appearance and vascularity, and post-treatment side effects. The dose range of bleomycin was 0.5-1.0 mg/kg, but not exceeding 15 mg in a single session. A maximum of four treatments were given in any given patient except for one, who presented with recurrence after a year of complete resolution. Therapeutic outcome was determined using review of ultrasound images and recorded clinical assessment. Treatment response was categorized as: (i) complete resolution [more than 90% reduction]; (ii) substantial reduction [more than 50% reduction]; (iii) mild reduction [25% reduction]; or, (iv) no improvement [<10% reduction].Results: A total of 30 patients (16 female, 14 male), ranging in age from 8 months to 48 years (mean age 10.2 years), were treated from 2009 to 2013. There were 23 hemangiomas. Seven were vascular malformations, of which five were lymphatic malformations and two were venous malformations. Twenty-eight lesions were located in the head and neck region, and two were peripheral. In 24 of the 30 patients (76%), treatment had been completed. In six patients (21%) treatment was ongoing at the time of this report. Seventeen of the 23 hemangiomas (74%) were completely resolved clinically and on ultrasound, five (22%) showed substantial improvement and one (4%) showed mild improvement. In five of the seven vascular malformations (71%) lymphatic malformations resolved completely, and two (29%) venous malformations showed substantial improvement. Of the 13 patients presenting with discoloration, there was complete resolution in one (7.7%), marked reduction in 11 (84.6%) and mild reduction in one (7.7%). Of seven patients presenting with pain, there was complete resolution in two (28.6%), marked reduction in two (28.6%), mild reduction in two (28.6%), and no improvement in one (14.3%). There were no pulmonary complications. Conclusion:Ultrasound-guided intralesional injection of bleomycin is an option to consider for the treatment of certain types of cutaneous hemangiomas and vascular malformations. Prospective studies should be undertaken to understand the various factors contributing to therapeutic success. Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Memon

Malik

Anjum

et al. 2016

JGR

View full text Add to dashboard Cite

show abstract

“…It is suitable for proliferating Hemangiomas responding poorly to steroids or laser therapy, for cutaneous superficial or mucosal Hemangiomas .Its concentration is 1mg/ml; for subcutaneous or deep, the concentration is 1.5-2mg/ml 34,35 . In case of Hemangiomas unresponsive to steroids or recurrence after steroids, Vincristine 0.5 -1 mg/ml can be given intravenously once a week over 6 weeks 36 .…”

Section: Hemangiomas Of Head and Neck -A Reviewmentioning

confidence: 99%

Hemangiomas of Head and Neck - A Review

Rohini¹,

Arularasan²,

Murugan³

2017

IOSR JDMS

View full text Add to dashboard Cite

“…It has been proven to be an easy, safe, and effective therapeutic modality in complicated cutaneous hemangiomas 13 and suitable for proliferative hemangiomas which respond poorly to steroids and/or laser therapy. Clinically, Pingyangmycin hydrochloride (8 mg/syringe) is dissolved with 2% lidocaine and then mixed with normal saline and dexamethasone (5 mg/1 mL).…”

mentioning

confidence: 99%

Treatment guideline for hemangiomas and vascular malformations of the head and neck

et al. 2009

View full text Add to dashboard Cite

Abstract:Vascular anomalies are among the most common congenital and neonatal dysmorphogenesis, which are separated into hemangiomas and vascular malformations. They can occur in various areas throughout the body, with 60% being located in the head and neck. The true mechanism of pathogenesis of vascular anomalies is still unclear. Various treatment methods have been reported, and there are still controversies over the selection of different treatment modalities. Based on the clinical and basic research and current literature, the Chinese Division of Oral and Maxillofacial Vascular Anomalies formulated a treatment guideline for hemangiomas and vascular malformations of the head and neck, which will be modified and updated periodically based on new medical evidence and research.

show abstract

Role of Intralesional Bleomycin in the Treatment of Complicated Hemangiomas: Prospective Clinical Study

Abstract: Intralesional injection of bleomycin is an easy, safe, and effective therapeutic modality in complicated cutaneous hemangiomas.

Cited by 22 publications

References 26 publications

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Hemangiomas of Head and Neck - A Review

Treatment guideline for hemangiomas and vascular malformations of the head and neck

Contact Info

Product

Resources

About